Literature DB >> 25853201

Dysbiosis in Celiac disease patients with persistent symptoms on gluten-free diet: a condition similar to that present in irritable bowel syndrome patients?

Giovanni Marasco1, Antonio Colecchia1, Davide Festi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25853201     DOI： 10.1038/ajg.2015.54

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  5 in total

1.  Presence of inulin and oligofructose in the diets of Americans.

Authors:  A J Moshfegh; J E Friday; J P Goldman; J K Ahuja
Journal:  J Nutr       Date:  1999-07       Impact factor: 4.798

2.  Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet.

Authors:  Pirjo Wacklin; Pilvi Laurikka; Katri Lindfors; Pekka Collin; Teea Salmi; Marja-Leena Lähdeaho; Päivi Saavalainen; Markku Mäki; Jaana Mättö; Kalle Kurppa; Katri Kaukinen
Journal:  Am J Gastroenterol       Date:  2014-11-18       Impact factor: 10.864

3.  Mucosal barrier defects in irritable bowel syndrome. Who left the door open?

Authors:  Giovanni Barbara
Journal:  Am J Gastroenterol       Date:  2006-06       Impact factor: 10.864

Review 4.  Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis.

Authors:  Anita Sainsbury; David S Sanders; Alexander C Ford
Journal:  Clin Gastroenterol Hepatol       Date:  2012-12-13       Impact factor: 11.382

Review 5.  Unraveling the ties between irritable bowel syndrome and intestinal microbiota.

Authors:  Sung Noh Hong; Poong-Lyul Rhee
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742
  5 in total
  7 in total

1.  Response to Marasco et al.

Authors:  Pirjo Wacklin; Pilvi Laurikka; Katri Lindfors; Jaana Mättö; Kalle Kurppa; Katri Kaukinen
Journal:  Am J Gastroenterol       Date:  2015-04       Impact factor: 10.864

Review 2.  Gut Microbiota and Celiac Disease.

Authors:  Giovanni Marasco; Anna Rita Di Biase; Ramona Schiumerini; Leonardo Henry Eusebi; Lorenzo Iughetti; Federico Ravaioli; Eleonora Scaioli; Antonio Colecchia; Davide Festi
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

3.  Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms.

Authors:  Blanca Serrano-Falcón; Sílvia Delgado-Aros; Fermín Mearin; Constanza Ciriza de Los Ríos; Jordi Serra; Miguel Mínguez; Miguel Montoro Huguet; Antonia Perelló; Cecilio Santander; Ángeles Pérez Aisa; Inmaculada Bañón-Rodríguez; Enrique Rey
Journal:  Therap Adv Gastroenterol       Date:  2019-08-05       Impact factor: 4.409

Review 4.  Probiotics, Prebiotics and Other Dietary Supplements for Gut Microbiota Modulation in Celiac Disease Patients.

Authors:  Giovanni Marasco; Giovanna Grazia Cirota; Benedetta Rossini; Lisa Lungaro; Anna Rita Di Biase; Antonio Colecchia; Umberto Volta; Roberto De Giorgio; Davide Festi; Giacomo Caio
Journal:  Nutrients       Date:  2020-09-02       Impact factor: 5.717

5.  Clinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years.

Authors:  Anna Rita Di Biase; Giovanni Marasco; Federico Ravaioli; Luigi Colecchia; Elton Dajti; Marco Lecis; Erica Passini; Luigina Vanessa Alemanni; Davide Festi; Lorenzo Iughetti; Antonio Colecchia
Journal:  Nutrients       Date:  2021-11-18       Impact factor: 5.717

6.  Probiotics and the Microbiome in Celiac Disease: A Randomised Controlled Trial.

Authors:  Joanna Harnett; Stephen P Myers; Margaret Rolfe
Journal:  Evid Based Complement Alternat Med       Date:  2016-07-21       Impact factor: 2.629

Review 7.  Contribution of Infectious Agents to the Development of Celiac Disease.

Authors:  Daniel Sánchez; Iva Hoffmanová; Adéla Szczepanková; Věra Hábová; Helena Tlaskalová-Hogenová
Journal:  Microorganisms       Date:  2021-03-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.